Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

Simple Summary CDK9, in combination with Cyclin T1, is one of the major regulators of RNA
Polymerase II mediated productive transcription of critical genes in any cell. The activity of …

Somatic mutations in DNA methyltransferase 3A (DNMT3A) are among the most frequent
alterations in clonal hematopoiesis (CH) and acute myeloid leukemia (AML), with a hotspot …

Introduction The emergence of resistance to the highly successful BCL2-directed therapy is
a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor …

Genome wide association studies (GWASs) have revealed several airway disease-
associated risk loci. Their role in the onset of asthma, allergic rhinitis (AR) or chronic …

Acute myeloid leukemia (AML) is a high-mortality malignancy with poor outcomes.
Azacitidine induces cell death and demonstrates treatment effectiveness against AML …

Cytogenomic characterization is crucial for the classification and risk stratification of acute
myeloid leukemia (AML), thereby facilitating therapeutic decision‐making. We examined the …

Nucleophosmin (NPM1) is a ubiquitously expressed nucleolar protein involved in ribosome
biogenesis, the maintenance of genomic integrity and the regulation of the ARF-p53 tumor …

Venetoclax is a promising agent in the treatment of acute myeloid leukemia (AML), though
its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim …

Purpose: The goal of this study was to characterize the activity of the covalent CDK7 inhibitor
THZ1 in multiple myeloma models. Experimental Design: Multiple myeloma lines were …